Creative Medical Technology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 4
- Market Cap
- -
- Introduction
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company, which engages in the provision of medical solutions for unmet immunological, urological, neurological, and orthopedic needs. It develops intellectual property portfolio utilizing stem cells and interrelated technologies for the treatment of erectile dysfunction and female sexual dysfunction. The company was founded on December 3, 1998 and is headquartered in Phoenix, AZ.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
- Conditions
- Chronic Low-back PainDegenerative Disc Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Creative Medical Technology Holdings Inc
- Target Recruit Count
- 30
- Registration Number
- NCT06053242
- Locations
- 🇺🇸
Spine and Wellness Centers of America, Aventura, Florida, United States
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
- Conditions
- Type 1 DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Creative Medical Technology Holdings Inc
- Target Recruit Count
- 18
- Registration Number
- NCT05626712
- Locations
- 🇺🇸
Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States
News
StemSpine Study Shows 90% Reduction in Opioid Use for Chronic Back Pain at 3-Year Follow-up
Creative Medical Technology's StemSpine pilot study demonstrates significant long-term success, with over 90% of chronic back pain patients eliminating opioid use three years post-treatment.
Creative Medical's CELZ-201-DDT Shows Promising Safety Profile in Phase 1/2 Degenerative Disc Disease Trial
Initial data from the first cohort of 10 participants demonstrates excellent safety profile for CELZ-201-DDT stem cell therapy, with no serious adverse events reported in degenerative disc disease treatment.